Burgaña Agoües Ander, Abellana Sangra Rosa, Ballestero-Téllez Mónica, Rajadell-Guiu Mireia, Garreta-Esteban Marc, Perez-Porcuna Tomàs M
Atenció Primària, Fundació Assitencial Mútua Terrassa, Terrassa. Spain. Fundació Docència i Recerca Mútua de Terrassa, Terrassa, Spain.
Departament Fonaments Clínics, Universitat de Barcelona, Barcelona, Spain.
Medicine (Baltimore). 2025 Mar 28;104(13):e41963. doi: 10.1097/MD.0000000000041963.
Dientamoeba fragilis is a globally widespread intestinal parasite and one of the most frequent in humans, often leading to primary care consultations. The pathogenic potential of this parasite remains unclear due to limited evidence and contradictory study results. This study investigated the pathogenicity of D fragilis, focusing on the critical knowledge gap regarding the relationship between parasite load and associated symptomatology. A prospective case-control study matched by household unit was conducted, considering individuals with gastrointestinal symptoms and D fragilis in stool as cases, and their asymptomatic household members with D fragilis in stools as controls. D fragilis detection was performed in parallel using light microscopy and real time-polymerase chain reaction. The study was carried out in 7 primary care centers over 12 months. Parasite load was measured as the number of trophozoites per field at a magnification of 40x by microscopy and by cycle threshold values in RT-PCR. A total of 218 individuals were recruited: 74 symptomatic cases and 144 household members, of whom 57 (39.6%) were D fragilis-positive asymptomatic controls. The proportion of individuals with D fragilis and a parasite load less than 1 trophozoite per field was higher in asymptomatic individuals (controls) than in symptomatic cases (47.7% vs 3.1%, respectively) (P < .001). Parasite load is associated with the presence of gastrointestinal symptoms, supporting the pathogenicity of D fragilis. Any diagnostic approach for D fragilis should incorporate or be complemented by quantitative information to accurately estimate parasite load and enhance treatment decision-making.
脆弱双核阿米巴是一种在全球广泛分布的肠道寄生虫,也是人类最常见的寄生虫之一,常导致患者前往初级保健机构就诊。由于证据有限且研究结果相互矛盾,这种寄生虫的致病潜力仍不明确。本研究调查了脆弱双核阿米巴的致病性,重点关注寄生虫载量与相关症状之间关系这一关键知识空白。开展了一项以家庭单位匹配的前瞻性病例对照研究,将有胃肠道症状且粪便中检测出脆弱双核阿米巴的个体作为病例,将其粪便中检测出脆弱双核阿米巴的无症状家庭成员作为对照。同时使用光学显微镜和实时聚合酶链反应进行脆弱双核阿米巴检测。该研究在7个初级保健中心进行,为期12个月。通过显微镜在40倍放大倍数下每个视野的滋养体数量以及实时荧光定量聚合酶链反应中的循环阈值来测量寄生虫载量。共招募了218名个体:74例有症状病例和144名家庭成员,其中57名(39.6%)为脆弱双核阿米巴阳性无症状对照。无症状个体(对照)中脆弱双核阿米巴且寄生虫载量低于每个视野1个滋养体的个体比例高于有症状病例(分别为47.7%和3.1%)(P < .001)。寄生虫载量与胃肠道症状的存在相关,支持脆弱双核阿米巴的致病性。任何针对脆弱双核阿米巴的诊断方法都应纳入定量信息或由其补充,以准确估计寄生虫载量并改善治疗决策。